A citation-based method for searching scientific literature

Maria E Arcila, Khedoudja Nafa, Jamie E Chaft, Natasha Rekhtman, Christopher Lau, Boris A Reva, Maureen F Zakowski, Mark G Kris, Marc Ladanyi. Mol Cancer Ther 2013
Times Cited: 289







List of co-cited articles
655 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
Geoffrey R Oxnard, Peter C Lo, Mizuki Nishino, Suzanne E Dahlberg, Neal I Lindeman, Mohit Butaney, David M Jackman, Bruce E Johnson, Pasi A Jänne. J Thorac Oncol 2013
203
51

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Hiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun, Natasha J Sng, Antonio R Lucena-Araujo, Wee-Lee Yeo, Mark S Huberman, David W Cohen, Sohei Nakayama, Kota Ishioka,[...]. Sci Transl Med 2013
333
45

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Jacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, Brett W Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal,[...]. Nat Med 2018
244
40

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.
Simon Vyse, Paul H Huang. Signal Transduct Target Ther 2019
153
39

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.
Jonathan W Riess, David R Gandara, Garrett M Frampton, Russell Madison, Nir Peled, Jose A Bufill, Grace K Dy, Sai-Hong Ignatius Ou, Philip J Stephens, John D McPherson,[...]. J Thorac Oncol 2018
103
37

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
36

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Shu Kam Mok, Martin Schuler, Nobuyuki Yamamoto, Chong-Jen Yu, Sai-Hong I Ou, Caicun Zhou,[...]. Lancet Oncol 2015
582
35


Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Keunchil Park, Eric B Haura, Natasha B Leighl, Paul Mitchell, Catherine A Shu, Nicolas Girard, Santiago Viteri, Ji-Youn Han, Sang-We Kim, Chee Khoon Lee,[...]. J Clin Oncol 2021
134
32

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
J Naidoo, C S Sima, K Rodriguez, N Busby, K Nafa, M Ladanyi, G J Riely, M G Kris, M E Arcila, H A Yu. Cancer 2015
133
31

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
Wenfeng Fang, Yihua Huang, Shaodong Hong, Zhonghan Zhang, Minghui Wang, Jiadi Gan, Wenjing Wang, Honglin Guo, Kai Wang, Li Zhang. BMC Cancer 2019
66
37

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Guangjian Yang, Jun Li, Haiyan Xu, Yaning Yang, Lu Yang, Fei Xu, Bing Xia, Viola W Zhu, Misako Nagasaka, Yan Yang,[...]. Lung Cancer 2020
43
58

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
Gregory J Riely, Joel W Neal, D Ross Camidge, Alexander I Spira, Zofia Piotrowska, Daniel B Costa, Anne S Tsao, Jyoti D Patel, Shirish M Gadgeel, Lyudmila Bazhenova,[...]. Cancer Discov 2021
91
27


Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
B van Veggel, J F Vilacha Madeira R Santos, S M S Hashemi, M S Paats, K Monkhorst, D A M Heideman, M Groves, T Radonic, E F Smit, E Schuuring,[...]. Lung Cancer 2020
47
48

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
22

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
Caicun Zhou, Suresh S Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J Riely, Tarek Mekhail, Danny Nguyen, Maria R Garcia Campelo, Enriqueta Felip,[...]. JAMA Oncol 2021
69
31

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.
Francois Gonzalvez, Sylvie Vincent, Theresa E Baker, Alexandra E Gould, Shuai Li, Scott D Wardwell, Sara Nadworny, Yaoyu Ning, Sen Zhang, Wei-Sheng Huang,[...]. Cancer Discov 2021
54
37

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.
M Beau-Faller, N Prim, A-M Ruppert, I Nanni-Metéllus, R Lacave, L Lacroix, F Escande, S Lizard, J-L Pretet, I Rouquette,[...]. Ann Oncol 2014
212
18

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors.
Pedro E N S Vasconcelos, Carol Gergis, Hollis Viray, Andreas Varkaris, Masanori Fujii, Deepa Rangachari, Paul A VanderLaan, Ikei S Kobayashi, Susumu S Kobayashi, Daniel B Costa. JTO Clin Res Rep 2020
31
58

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
17

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
16

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita,[...]. N Engl J Med 2010
16

EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP).
Andrés F Cardona, Leonardo Rojas, Zyanya Lucia Zatarain-Barrón, Helano C Freitas, Sara T Granados, Omar Castillo, George Oblitas, Luis Corrales, Christian D Castro, Alejandro Ruiz-Patiño,[...]. Lung Cancer 2018
35
45

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen,[...]. N Engl J Med 2017
16

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
16

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Jang Ho Cho, Sung Hee Lim, Ho Jung An, Ki Hwan Kim, Keon Uk Park, Eun Joo Kang, Yoon Hee Choi, Mi Sun Ahn, Myung Hee Lee, Jong-Mu Sun,[...]. J Clin Oncol 2020
150
15

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rolf Linke, Rafael Rosell, Jesus Corral,[...]. Lancet Oncol 2017
639
15

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.
Jiyeon Yun, Soo-Hwan Lee, Seok-Young Kim, Seo-Yoon Jeong, Jae-Hwan Kim, Kyoung-Ho Pyo, Chae-Won Park, Seong Gu Heo, Mi Ran Yun, Sangbin Lim,[...]. Cancer Discov 2020
94
15

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.
Shinichi Hasako, Miki Terasaka, Naomi Abe, Takao Uno, Hirokazu Ohsawa, Akihiro Hashimoto, Ryoto Fujita, Kenji Tanaka, Takashige Okayama, Renu Wadhwa,[...]. Mol Cancer Ther 2018
48
27

TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.
Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Mikiko Shibuya, Naomi Abe, Toshiharu Komori, Tomonori Haruma, Miki Terasaka,[...]. Mol Cancer Res 2019
29
44

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
Jordi Remon, Lizza E L Hendriks, Andres F Cardona, Benjamin Besse. Cancer Treat Rev 2020
50
26

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Darren A E Cross, Susan E Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A Nebhan, Paula J Spitzler, Jonathon P Orme, M Raymond V Finlay, Richard A Ward, Martine J Mellor,[...]. Cancer Discov 2014
12

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.
Toshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani, Junko Hamamoto, Ayano Oashi, Kota Ishioka, Daisuke Arai, Shigenari Nukaga, Masayoshi Miyawaki, Ichiro Kawada,[...]. Oncotarget 2015
108
12

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Takayuki Kosaka, Junko Tanizaki, Raymond M Paranal, Hideki Endoh, Christine Lydon, Marzia Capelletti, Claire E Repellin, Jihyun Choi, Atsuko Ogino, Antonio Calles,[...]. Cancer Res 2017
89
13

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Nicolas Floc'h, Matthew J Martin, Jonathan W Riess, Jonathan P Orme, Anna D Staniszewska, Ludovic Ménard, Maria Emanuela Cuomo, Daniel J O'Neill, Richard A Ward, M Raymond V Finlay,[...]. Mol Cancer Ther 2018
62
17


Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Alessandro Leonetti, Sugandhi Sharma, Roberta Minari, Paola Perego, Elisa Giovannetti, Marcello Tiseo. Br J Cancer 2019
410
11

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Maria E Arcila, Jamie E Chaft, Khedoudja Nafa, Sinchita Roy-Chowdhuri, Christopher Lau, Michael Zaidinski, Paul K Paik, Maureen F Zakowski, Mark G Kris, Marc Ladanyi. Clin Cancer Res 2012
300
11

Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
Bianca van Veggel, Adrianus J de Langen, Sayed M S Hashemi, Kim Monkhorst, Daniëlle A M Heideman, Erik Thunnissen, Egbert F Smit. J Thorac Oncol 2018
45
24


EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib--Letter.
Pei Jye Voon, Dana Wai Yi Tsui, Nitzan Rosenfeld, Tan Min Chin. Mol Cancer Ther 2013
34
32

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Hai-Yan Tu, E-E Ke, Jin-Ji Yang, Yue-Li Sun, Hong-Hong Yan, Ming-Ying Zheng, Xiao-Yan Bai, Zhen Wang, Jian Su, Zhi-Hong Chen,[...]. Lung Cancer 2017
119
11

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.
Jenn-Yu Wu, Shang-Gin Wu, Chih-Hsin Yang, Chien-Hung Gow, Yih-Leong Chang, Chong-Jen Yu, Jin-Yuan Shih, Pan-Chyr Yang. Clin Cancer Res 2008
240
11

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
11

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Lecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer,[...]. J Clin Oncol 2013
11


Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Kaiyan Chen, Guoqiang Pan, Guoping Cheng, Fanrong Zhang, Yanjun Xu, Zhiyu Huang, Yun Fan. Thorac Cancer 2021
28
39

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.
Z Piotrowska, D B Costa, G R Oxnard, M Huberman, J F Gainor, I T Lennes, A Muzikansky, A T Shaw, C G Azzoli, R S Heist,[...]. Ann Oncol 2018
42
23

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B Turke, Panos Fidias, Kristin Bergethon, Alice T Shaw, Scott Gettinger, Arjola K Cosper,[...]. Sci Transl Med 2011
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.